Medical Excellence Capital

Medical Excellence Capital (MEC) is a New York-based early-stage venture capital firm focused on life sciences and healthcare innovation. Founded in 2020, MEC combines accomplished investment professionals and operators with a proprietary global network of physician-scientists to create a unique platform for nurturing transformative technologies in precision health. The firm specializes in company creation, seed, Series A, and Series B investments, targeting innovations that address significant unmet medical needs.

MEC’s investment strategy centers on disruptive technologies such as cell therapy, gene therapy, AI/ML applied to drug discovery, synthetic biology, and regenerative medicine. The firm leverages its deep industry expertise and extensive network to accelerate the development of breakthrough therapies and diagnostics. MEC’s Scientific Advisory Board, comprised of leading innovators in regenerative medicine, gene therapy, and mitochondrial medicine, provides critical perspective and value to portfolio companies.

With a team of seasoned venture capitalists, company builders, and operators, MEC supports early-stage ventures from inception through growth. The firm is closely aligned with the Medical Excellence Group, a global private health advisory network, further enhancing its ability to identify and advance high-impact opportunities in the life sciences sector.